WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function

Oncogene

Volumn 32, Issue 40, 2013, Pages 4737-4747

  Pandolfi, S ^a   Montagnani, V ^a   Penachioni, J Y ^a   Vinci, M C ^a   Olivito, B ^b   Borgognoni, L ^c   Stecca, B ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

cancer stem cells; GLI1; Hedgehog; melanoma; self renewal; WIP1; xenograft

Indexed keywords

CYCLOHEXIMIDE; CYCLOPAMINE; PHOSPHATASE; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG; WIP1 PHOSPHATASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

CELL NUCLEUS; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

ERINACEIDAE;

EID: 84885185198     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.502     Document Type: Article

References (75)

1. Ingham PW, McMahon AP. Hedgehog signaling in animal Development: Paradigms and principles. Genes Dev 2001; 15: 3059-3087.
2. Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev 2008; 22: 2454-2472.
3. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 324-331.
4. Teglund S, Toftgård R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010; 1805: 181-208.
5. Ng JM, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.
6. Rohatgi R, Scott MP. Patching the gaps in Hedgehog signalling. Nat Cell Biol 2007; 9: 1005-1009.
7. Jiang J, Hui CC. Hedgehog signaling in Development and cancer. Dev Cell 2008; 15: 801-812.
8. Stecca B, Ruiz i Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2010; 2: 84-95.
9. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-851.
10. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-1671.
11. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-92.
12. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 2006; 26: 6283-6298.
13. de nnler S, André J, Alexaki I, Li A, Magnaldo T, ten Dijke P et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007; 67: 6981-6986.
14. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007; 104: 5895-5900.
15. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernández- Zapico ME et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009; 23: 24-36.
16. Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K et al. Hedgehog-EGFR cooperation response genes de termine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012; 4: 218-233.
17. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012; 21: 374-387.
18. Stecca B, Ruiz i Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 2009; 28: 663-676.
19. Hershko T, Korotayev K, Polager S, Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J Biol Chem 2006; 281: 31309-31316.
20. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94: 6048-6053.
21. Choi J, Nannenga B, de midov ON, Bulavin DV, Cooney A, Brayton C et al. Mice de ficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit de fects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 2002; 22: 1094-1105.
22. Zhu YH, Zhang CW, Lu L, de midov ON, Sun L, Yang L et al. Wip1 regulates the generation of new neural cells in the adult olfactory bulb through p53-dependent cell cycle control. Stem Cells 2009; 27: 1433-1442.
23. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W, Bulavin DV. Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. Cell Metab 2012; 16: 68-80.
24. Bulavin DV, de midov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet 2002; 31: 210-215.
25. Li J, Yang Y, Peng Y, Austin RJ, Van Eyndhoven WG, Nguyen KC et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002; 31: 133-134.
26. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9: 1995-2004.
27. Castellino RC, de bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA et al. Medulloblastomas overexpress the p53-Inactivating oncogene Wip1/PPM1D. J Neurooncol 2008; 86: 245-256.
28. Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, Sutton R et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006; 45: 594-604.
29. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004; 36: 343-350.
30. de midov ON, Timofeev O, Lwin HN, Kek C, Appella E, Bulavin DV. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 2007; 1: 180-190.
31. de midov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007; 26: 2502-2506.
32. Lu X, Nannenga B, Donehower LA. PPM1D de phosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005; 19: 1162-1174.
33. Shreeram S, de midov ON, Hee WK, Yamaguchi H, Onishi N, Kek C et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 2006; 23: 757-764.
34. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 2006; 13: 1170-1180.
35. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H et al. P53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19: 6517-6526.
36. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007; 12: 342-354.
37. Cha H, Lowe JM, Li H, Lee JS, Belova GI, Bulavin DV et al. Wip1 directly de phosphorylates gamma-H2AX and attenuates the DNA damage response. Cancer Res 2010; 70: 4112-4122.
38. Liang C, Guo E, Lu S, Wang S, Kang C, Chang L et al. Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas. Brain Res 2012; 1444: 65-75.
39. Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 2008; 27: 1036-1044.
40. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA 2002; 99: 14071-14076.
41. Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY, Reiter JF. Vertebrate Smoothened functions at the primary cilium. Nature 2005; 437: 1018-1021.
42. Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. Science 2007; 317: 372-376.
43. Pan Y, Wang B. A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein de gradation by the proteasome. J Biol Chem 2007; 282: 10846-10852.
44. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual de gradation signals control Gli protein stability and tumor formation. Genes Dev 2006; 20: 276-281.
45. Kogerman P, Grimm T, Kogerman L, Krause D, Undén AB, Sandstedt B et al. Mammalian Suppressor-of-Fused modulates nuclear-cytoplasmic shuttling of GLI1. Nat Cell Biol 1999; 1: 312-319.
46. Parssinen J, Alarmo EL, Karhu R, Kallioniemi A. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet Cytogenet 2008; 182: 33-39.
47. Clement V, Sanchez P, de tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOGGLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172.
48. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 4048-4053.
49. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signaling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009; 1: 338-351.
50. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
51. Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B et al. HEDGEHOG-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 2012; 30: 1808-1818.
52. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H et al. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010; 70: 7176-7186.
53. Doucette TA, Yang Y, Pedone C, Kim JY, Dubuc A, Northcott PD et al. WIP1 enhances tumor formation in a Sonic Hedgehog-dependent model of medulloblastoma. Neurosurgery 2011; 70: 1003-1010.
54. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406: 1005-1009.
55. Jia H, Liu Y, Yan W, Jia J. PP4 and PP2A regulate Hedgehog signaling by controlling Smo and Ci phosphorylation. Development 2009; 136: 307-316.
56. Krauss S, Foerster J, Schneider R, Schweiger S. Protein phosphatase 2A and rapamycin regulate the nuclear localization and activity of the transcription factor GLI3. Cancer Res 2008; 68: 4658-4665.
57. Krauss S, So J, Hambrock M, Kohler A, Kunath M, Scharff C et al. Point mutations in GLI3 lead to misregulation of its subcellular localization. PLoS One 2009; 4: E7471.
58. Rorick AM, Mei W, Liette NL, Phiel C, El-Hodiri HM, Yang J. PP2A:B56epsilon is required for eye induction and eye field separation. Dev Biol 2007; 302: 477-493.
59. Jin Z, Mei W, Strack S, Jia J, Yang J. The antagonistic action of B56-containing protein phosphatase 2As and casein kinase 2 controls the phosphorylation and Gli turnover function of Daz interacting protein 1. J Biol Chem 2011; 286: 36171-36179.
60. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008; 27: 123-135.
61. Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci USA 2008; 105: 4838-4843.
62. Lai K, Robertson MJ, Schaffer DV. The sonic hedgehog signaling system as a bistable genetic switch. Biophys J 2004; 86: 2748-2757.
63. Lai K, Kaspar BK, Gage FH, Schaffer DV. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 2003; 6: 21-27.
64. Chin L, Garraway LA, Fisher De . Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 2006; 20: 2149-2182.
65. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857.
66. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS et al. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by upregulating osteopontin. J Biol Chem 2009; 284: 22888-22897.
67. Castresana JS, Rubio MP, Vázquez JJ, Idoate M, Sober AJ, Seizinger BR et al. Lack of allelic de letion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993; 55: 562-565.
68. Low JA, de sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28: 5321-5326.
69. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, Appella E. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry 2006; 45: 13193-13202.
70. Hayashi R, Tanoue K, Durell SR, Chatterjee DK, Jenkins LM, Appella DH et al. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry 2011; 50: 4537-4549.
71. Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA et al. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet 2005; 14: 2181-2188.
72. Lindqvist A, de bruijn M, Macurek L, Brá s A, Mensinga A, Bruinsma W et al. Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. EMBO J 2009; 28: 3196-3206.
73. Sasaki H, Hui C, Nakafuku M, Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 1997; 124: 1313-1322.
74. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
75. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.